Skip to content
The Outlook for Biotech in 2018 episode artwork

Jan 4, 2018 19 min

The Outlook for Biotech in 2018

from The Bio Report Hosted by Levine Media Group

We conclude our biotech review-preview series with our final installment this week as we take a look at the year ahead as the industry readies for the JPMorgan Healthcare Conference. We spoke to Jon Gardner, U.S. News Editor for EP Vantage, about the EP Vantage 2018 Preview(http://bit.ly/2CT2RDP), the outlook for big-value drug launches, and whether dealmaking or clinical success will drive stock prices in 2018. As a note, this podcast was recorded prior to Spark Therapeutics announcement of its pricing for its gene therapy Luxturna.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

The Outlook for Biotech in 2018

0:00 19:47

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 19 minutes long.

When was this The Bio Report episode published?

This episode was published on January 4, 2018.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.